Skip to main content
P

PharmaEssentia Corporation — Investor Relations & Filings

Ticker · 6446 LEI · 54930001GNQLDIFASK68 TW Manufacturing
Open in API
Filings indexed 23 across all filing types
Latest filing 2026-04-09 Capital/Financing Update
Country TW Taiwan
Listing TW 6446

About PharmaEssentia Corporation

http://www.PharmaEssentia.com

PharmaEssentia Corporation is a fully integrated global entity focused on the discovery, development, and commercialization of novel therapies for hematologic diseases and oncology. The company leverages a proprietary PEGylation technology platform to engineer long-acting protein therapeutics designed to improve patient outcomes. Its flagship product, BESREMi® (Ropeginterferon alfa-2b), represents a significant advancement in the treatment of Polycythemia Vera, having received regulatory approval from the US FDA and EU EMA as a first-line therapy. PharmaEssentia operates a comprehensive value chain, including internal R&D, clinical trial management, and cGMP-certified manufacturing facilities. By addressing unmet medical needs in rare blood disorders and various cancers, the company aims to deliver best-in-class treatments to global markets through its integrated research and production capabilities.

Recent filings

Filing Released Lang Actions
公告本公司董事會決議於美國波多黎各投資設立子公司PharmaEssentia Puerto Rico LLC（更新交易總金額）
Capital/Financing Update Classification · 1% confidence The document is a regulatory disclosure from Taiwan’s Market Observation Post System showing a board resolution to invest in and establish a US subsidiary and an update on the transaction total amount. It details investment amounts, board approval dates, related party status, and funding sources. This is not an earnings release, M&A takeover bid, or director transaction, nor is it reporting full financials (10-K/IR). It is specifically an update to the company’s capital deployment/financing plan (investment amount), so it best fits the Capital/Financing Update category (CAP).
2026-04-09 Chinese
公告本公司董事會決議購買Forus Therapeutics Inc. 100%股權
M&A Activity Classification · 1% confidence The document is a public disclosure by a listed company (Taiwan) announcing a board resolution to purchase 100% of Forus Therapeutics Inc’s equity. It details the acquisition terms, prices, transaction parties, valuation, and related corporate governance approvals. This clearly falls under M&A activity (announcements/documents about takeover or merger transactions). It is not a regulatory notice of report publication nor a simple earnings or management report, but a specific asset acquisition announcement, matching the M&A Activity category (TAR).
2026-04-09 Chinese
115年03月內部人持股異動(事後)
Director's Dealing Classification · 1% confidence The document is a detailed table disclosing shareholdings and monthly changes (increases/decreases) for directors, executives, and their related parties, consistent with insider share transaction reporting. It is not a general corporate report, but a regulatory disclosure of director/executive personal shareholdings and movements. Therefore, it falls under Director's Dealing (insider transactions).
2026-04-09 Chinese
115年03月董事會成員及持股
Director's Dealing Classification · 1% confidence The document is a regulatory disclosure detailing shareholdings and pledged shares of the company’s directors, independent directors, and senior officers. It is not an earnings release, proxy statement, or annual report. Instead it matches the “Director’s Dealing” category, which covers insider share transaction and holding disclosures by directors and executives.
2026-04-09 Chinese
115年3月背書保證與資金貸與
Regulatory Filings Classification · 1% confidence The document is extremely short (25 characters) and contains a generic notice from a public information system (“公開資訊觀測站”) stating no data is found. It does not convey any substantive financial report, announcement of a meeting, or regulatory filing in a specific category. As a result, it falls under the fallback category of Regulatory Filings (RNS).
2026-04-05 Chinese
115年3月營業收入
Regulatory Filings Classification · 1% confidence The document is a monthly revenue summary table provided on Taiwan’s Market Observation Post System (MOPS) by a listed company. It is a regulatory-required disclosure of operating revenues, not an AGM presentation, earnings release, annual or interim report, nor any financing, governance or legal notice. It is a generic regulatory announcement (miscellaneous filing) of monthly/cumulative revenue figures. Therefore, it falls under the fallback category for regulatory filings.
2026-04-05 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.